Johnson & Johnson (JNJ)

139.20
0.70 0.50
NYSE
Prev Close 139.90
Open 139.65
Day Low/High 138.86 / 140.14
52 Wk Low/High 118.62 / 148.99
Volume 5.53M
Exchange NYSE
Shares Outstanding 2662.77B
Market Cap 367.01B
Div & Yield N.A. (N.A)

Latest News

What Is Berkshire Hathaway and What Does It Do in 2019?

What Is Berkshire Hathaway and What Does It Do in 2019?

Berkshire Hathaway is a holding company led by Warren Buffett that owns dozens of subsidiaries in the tech, insurance, and food industries (among many others), and whose stock is the most expensive stock you can own.

Weekly Roundup

Markets see flat trading for first week of earnings season.

Be Careful With Healthcare Stocks Here

Be Careful With Healthcare Stocks Here

Especially when healthcare CEOs discus political issues with analysts and reporters.

Thoughts on UnitedHealth Group

We do not believe members need to rush in just yet.

Johnson & Johnson and United Healthcare Face a Series of Obstacles

Johnson & Johnson and United Healthcare Face a Series of Obstacles

Recapping a big day of earnings for both names.

Stocks End Up but UnitedHealth Weakness Slows Dow Advance

Stocks End Up but UnitedHealth Weakness Slows Dow Advance

Stocks are higher but a fall in shares of UnitedHealth limited gains for the Dow Jones Industrial Average.

JNJ Had a Strong Quarter but Near-Term Headwinds Keep Us at a TWO

We believe the stock will have a difficult time pushing to new all-time highs past the $149 level until the company's legal issues are behind it.

Johnson & Johnson Stock Could Break Out on Earnings Beat

Johnson & Johnson Stock Could Break Out on Earnings Beat

Johnson & Johnson stock is on the verge of breaking out after reporting earnings. See this important level now.

Video: Jim's Daily Rundown for Tuesday

Jim discusses this morning's Viacom buy, earnings from Johnson & Johnson and UnitedHealth Group, and Anadarko Petroleum. In addition, he answers a club member's question!

Johnson & Johnson Rises After Topping First-Quarter Earnings Forecasts

Johnson & Johnson Rises After Topping First-Quarter Earnings Forecasts

Healthcare giant Johnson & Johnson reports first-quarter earnings lower than a year earlier but still above analysts' forecasts.

Fed's Evans Knows Nothing, China Q1 GDP, Trading Netflix: Market Recon

Fed's Evans Knows Nothing, China Q1 GDP, Trading Netflix: Market Recon

When Netflix reports earnings tonight, what will likely matter above all else for now will be subscriber growth.

Netflix, Bank of America, IBM, Hulu and Notre Dame - 5 Things You Must Know

Netflix, Bank of America, IBM, Hulu and Notre Dame - 5 Things You Must Know

U.S. stock futures are higher as Wall Street's focus remains on corporate earnings reports; Bank of America, UnitedHealth Group, Netflix and IBM report earnings; Hulu buys out AT&T's stake in the streaming service for $1.43 billion.

Johnson & Johnson Reports 2019 First-Quarter Results:

Johnson & Johnson Reports 2019 First-Quarter Results:

- Sales of $20.0 billion reflecting growth of 0.1%, operational growth of 3.9%* and adjusted operational growth of 5.5%*

What We Are Watching With This Week's Earnings

UnitedHealth Group and Johnson & Johnson report Tuesday, Abbott Labs on Wednesday, and Honeywell, Schlumberger and Danaher on Thursday.

How to Trade Johnson & Johnson During Earnings Week

How to Trade Johnson & Johnson During Earnings Week

The biggest challenge is even if JNJ beats and raises guidance, the overhang of litigation could still prevent overzealous trading.

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.

Weekly Roundup

Stocks grind higher as earnings season kicks indexes into gear.

Johnson & Johnson Is a Great Company Trading at a Fair Price

Johnson & Johnson Is a Great Company Trading at a Fair Price

Drug companies continue to be scapegoats on Capitol Hill and the talcum powder issues aren't disappearing for J&J. Yet its operations and balance sheet are stellar and J&J shares trade at a discount to historical averages.

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.

Weekly Roundup

Markets pushed higher as we gear up for first-quarter results starting next week.

Johnson & Johnson Announces Completion Of Acquisition Of Auris Health, Inc.

Johnson & Johnson Announces Completion Of Acquisition Of Auris Health, Inc.

Auris will Enable Johnson & Johnson to Deliver on the Promise of Digital Surgery and Drive Better Outcomes for Patients

Last Week's Portfolio Changes

We raised two price targets and downgraded a position last week.

Weekly Roundup

Markets move higher as investors shrug off slowing growth to focus on U.S.-China Trade Deal hopes.

More Mud on Johnson & Johnson?

More Mud on Johnson & Johnson?

There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.

Johnson & Johnson Vision Announces Availability Of ACUVUE OASYS With TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY In The U.S.

Johnson & Johnson Vision Announces Availability Of ACUVUE OASYS With TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY In The U.S.

Baseball Superstar Bryce Harper Named Ambassador for New Contact Lenses that Seamlessly Adapt to Changing Light Conditions[1]

Markets Lower Wednesday but We Have Been Raising Cash

We have long cautioned on our member-only conference calls about the flush of IPOs coming to market and its impact to stocks.

Locking in Gains in Three More Positions This Morning

Our concern is about how the law of supply and demand will affect prices, and no one ever got hurt taking a profit.

TheStreet Quant Rating: B+ (Buy)